



(51) International Patent Classification:

A61K 39/00 (2006.01) C07K 16/28 (2006.01)
A61P 35/00 (2006.01)

(21) International Application Number:

PCT/US2022/039390

(22) International Filing Date:

04 August 2022 (04.08.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/229,839 05 August 2021 (05.08.2021) US
63/241,837 08 September 2021 (08.09.2021) US
63/270,642 22 October 2021 (22.10.2021) US

(71) Applicant: **GO THERAPEUTICS, INC.** [US/US]; 1
Broadway, Cambridge, Massachusetts 02142 (US).

(72) Inventors: **WANDALL, Hans**; c/o GO THERAPEUTICS,
INC., 1 Broadway, Cambridge, Massachusetts 02142 (US).
SCHNABEL, Julia; c/o GO THERAPEUTICS, INC., 1

Broadway, Cambridge, Massachusetts 02142 (US). **TAN, Edwin**; c/o GO THERAPEUTICS, INC., 1 Broadway, Cambridge, Massachusetts 02142 (US). **GROEN, Aaron**; c/o GO THERAPEUTICS, INC., 1 Broadway, Cambridge, Massachusetts 02142 (US). **MORSE JR., Richard Johnson**; c/o GO THERAPEUTICS, INC., 1 Broadway, Cambridge, Massachusetts 02142 (US).

(74) Agent: **ABU-SHAAR, Muna** et al.; Biospark Intellectual Property Law, 1 Broadway, 14th Floor, Cambridge, Massachusetts 02142 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,

(54) Title: ANTI-GLYCO-MUC4 ANTIBODIES AND THEIR USES




FIG. 1A

(57) Abstract: The present disclosure relates to anti-glyco-MUC4 antibodies and antigen binding fragments thereof that specifically bind to a cancer-specific glycosylation variant of MUC4 and related fusion proteins and antibody-drug conjugates, as well as nucleic acids encoding such biomolecules. The present disclosure further relates to use of the antibodies, antigen-binding fragments, fusion proteins, antibody-drug conjugates and nucleic acids for cancer therapy.

[Continued on next page]

TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*